Compare FULTP & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Fulton Financial Corporation Depositary Shares Each Representing a 1/40th Interest in a Share of Fixed Rate Non-Cumulative Perpetual Preferred Stock Series A
Current Price
| Metric | FULTP | XGN |
|---|---|---|
| Founded | N/A | 2002 |
| Country | United States | United States |
| Employees | 3400 | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 138.9M |
| IPO Year | N/A | 2019 |
| Metric | FULTP | XGN |
|---|---|---|
| Price | $19.18 | $6.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $13.67 |
| AVG Volume (30 Days) | N/A | ★ 259.1K |
| Earning Date | N/A | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $63,599,000.00 |
| Revenue This Year | N/A | $21.76 |
| Revenue Next Year | N/A | $15.63 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 14.08 |
| 52 Week Low | N/A | $2.67 |
| 52 Week High | N/A | $12.23 |
| Indicator | FULTP | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 34.08 | 24.58 |
| Support Level | $19.06 | $5.84 |
| Resistance Level | $19.33 | $6.34 |
| Average True Range (ATR) | 0.18 | 0.32 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 5.00 | 9.31 |
Fulton Financial Corp is a U.S.-based financial services holding company that operates in five states: Pennsylvania, Delaware, Maryland, New Jersey and Virginia. It offers a range of consumer and commercial banking products and services, such as checking and savings deposit products and loan products. It offers consumer and commercial banking products and services, as well as wealth management products and services. The bank derives its revenue from non-interest income, led by its Wealth Management division.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.